S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NYSEAMERICAN:ATNM

Actinium Pharmaceuticals - ATNM Stock Forecast, Price & News

$5.41
-0.06 (-1.10%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.39
▼
$5.55
50-Day Range
N/A
52-Week Range
$4.41
▼
$10.30
Volume
47,038 shs
Average Volume
433,857 shs
Market Capitalization
$128.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.67

Actinium Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
485.3% Upside
$31.67 Price Target
Short Interest
Healthy
1.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.19mentions of Actinium Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.14) to ($1.36) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

See Top Rated MarketRank™ Stocks Here
ATNM stock logo

About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Receive ATNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ATNM Stock News Headlines

August 9, 2022 | finance.yahoo.com
Cholesterol API Market to Surpass US$ 426.9 Mn by 2032 Amid Surging Use in Liposome Formulation | Future Market Insights, Inc.
August 9, 2022 | finance.yahoo.com
Global API Management Market Report 2022: A $13.7 Billion Market by 2027 - Growing Need for APIs to Increase Digital Transformation
August 9, 2022 | Weiss Ratings (Ad)
Inflation Emergency to Disrupt Your Financial Future?
No doubt, we’re in an inflation emergency. It’s driving up prices more quickly than anything we’ve seen in our lifetime. And it’s barely begun. What impact will this change have on your money? How can you prepare starting right now? Watch the emergency briefing from Expert Sean Brodrick. pixel
August 9, 2022 | apnews.com
Contrast Security’s API Security Solution Further Enhances Protection Against Vulnerabilities and Zero Day Attacks
August 9, 2022 | markets.businessinsider.com
Traceable AI Addresses API-based Data Security and Fraud Attacks in Latest Platform Update
August 5, 2022 | americanbankingnews.com
Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Sees Large Drop in Short Interest
July 23, 2022 | americanbankingnews.com
Q2 2022 Earnings Forecast for Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Issued By William Blair
July 22, 2022 | americanbankingnews.com
Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Short Interest Down 20.5% in June
August 9, 2022 | Investing Daily (Ad)
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
July 17, 2022 | seekingalpha.com
ATNM Actinium Pharmaceuticals, Inc.
May 19, 2022 | finance.yahoo.com
Has Alkermes (ALKS) Outpaced Other Medical Stocks This Year?
April 25, 2022 | nasdaq.com
Actinium: All Patients Receiving Iomab-B Able To Proceed To Bone Marrow Transplant In Phase 3 Trial
April 25, 2022 | finance.yahoo.com
Actinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in the Phase 3 SIERRA Trial Successfully Engrafted at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
April 19, 2022 | finance.yahoo.com
Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
April 13, 2022 | finance.yahoo.com
Actinium (ATNM) Up on Commercialization Deal With Immedica
April 12, 2022 | benzinga.com
Actinium Shares See Spike In Volume As Hearing Traders Circulate William Blair Note Showing ~$12.50 Price Target
April 12, 2022 | msn.com
Why Actinium Pharmaceuticals Stock Is Surging
April 12, 2022 | msn.com
Benzinga's Daily Brief On Trending Tickers For April 12, 2022: Veru, Kohl's Corporation, BioCardia, And More
April 12, 2022 | nasdaq.com
Actinium Pharma In Deal With Immedica For Iomab-B; Sees Up To $452 Mln Milestone Payments
April 12, 2022 | seekingalpha.com
Actinium gains on agreement with Immedica Pharma for conditioning agent
April 12, 2022 | finance.yahoo.com
Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa
April 11, 2022 | finance.yahoo.com
Actinium Pharmaceuticals Presents Preclinical Data at AACR Showing HER3 Targeted Radiotherapy Combined with the CD47 Immunotherapy Magrolimab Increases the Anti-tumor Effect
February 22, 2022 | finance.yahoo.com
Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors
January 26, 2022 | nasdaq.com
Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (ATNM)
January 21, 2022 | finance.yahoo.com
ATNM Jan 2022 7.500 call
January 14, 2022 | nasdaq.com
Actinium Pharmaceuticals Inc. Shares Approach 52-Week Low - Market Mover
January 5, 2022 | seekingalpha.com
Actinium Pharma collaborates with EpicentRx to develop therapy for acute myeloid leukemia
See More Headlines
Receive ATNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ATNM Company Calendar

Last Earnings
5/13/2022
Today
8/09/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:ATNM
Previous Symbol
AMEX:ATNM
CUSIP
N/A
CIK
N/A
Web
www.actiniumpharmaceuticals.com
Phone
(646) 677-3870
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$31.67
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+485.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-22,220,000.00
Net Margins
-2,165.56%
Pretax Margin
-2,165.56%
Return on Equity
-32.48%
Return on Assets
-30.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.66
Quick Ratio
19.87

Sales & Book Value

Annual Sales
$1.14 million
Price / Sales
112.87
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.50 per share
Price / Book
1.55

Miscellaneous

Outstanding Shares
23,785,000
Free Float
21,745,000
Market Cap
$128.68 million
Optionable
Optionable
Beta
0.48

Key Executives

  • Mr. Sandesh C. Seth M.B.A. (Age 58)
    M.S., MBA, Chairman & CEO
    Comp: $1.04M
  • Mr. Steven O'Loughlin BS (Age 36)
    CFO & Corp. Sec.
    Comp: $520k
  • Dr. Paul Diamond Esq.
    Ph.D., VP of Patent & Legal Counsel
  • Dr. David Gould
    Sr. VP of Corp. Devel. & Corp. Affairs
  • Dr. Bernie Cunningham
    Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management
  • Dr. Qing Liang
    VP & Head of Radiation Sciences
  • Dr. Robert N. Daly M.S.
    Ph.D., VP & Head of Clinical Operations
  • Dr. Mamata Gokhale
    VP & Global Head of Regulatory Affairs
  • Dr. Avinash Desai M.D.
    Chief Medical Officer
  • Dr. Arun Swaminathan Ph.D.
    Chief Bus. & Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ATNM Stock - Frequently Asked Questions

Should I buy or sell Actinium Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATNM shares.
View ATNM analyst ratings or view top-rated stocks.

What is Actinium Pharmaceuticals' stock price forecast for 2022?

3 brokers have issued 1 year target prices for Actinium Pharmaceuticals' stock. Their ATNM share price forecasts range from $25.00 to $45.00. On average, they predict the company's stock price to reach $31.67 in the next twelve months. This suggests a possible upside of 483.2% from the stock's current price.
View analysts price targets for ATNM or view top-rated stocks among Wall Street analysts.

How has Actinium Pharmaceuticals' stock performed in 2022?

Actinium Pharmaceuticals' stock was trading at $6.05 at the beginning of 2022. Since then, ATNM stock has decreased by 10.2% and is now trading at $5.43.
View the best growth stocks for 2022 here.

Are investors shorting Actinium Pharmaceuticals?

Actinium Pharmaceuticals saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 371,700 shares, a decrease of 15.8% from the June 30th total of 441,500 shares. Based on an average daily trading volume, of 226,200 shares, the days-to-cover ratio is presently 1.6 days.
View Actinium Pharmaceuticals' Short Interest.

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) issued its earnings results on Friday, May, 13th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.08. The biotechnology company earned $0.94 million during the quarter. Actinium Pharmaceuticals had a negative net margin of 2,165.56% and a negative trailing twelve-month return on equity of 32.48%.

When did Actinium Pharmaceuticals' stock split?

Actinium Pharmaceuticals's stock reverse split on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO).

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Actinium Pharmaceuticals' stock price today?

One share of ATNM stock can currently be purchased for approximately $5.43.

How much money does Actinium Pharmaceuticals make?

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) has a market capitalization of $129.15 million and generates $1.14 million in revenue each year.

How many employees does Actinium Pharmaceuticals have?

Actinium Pharmaceuticals employs 32 workers across the globe.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The official website for the company is www.actiniumpharmaceuticals.com. The biotechnology company can be reached via phone at (646) 677-3870 or via email at investorrelations@actiniumpharma.com.

This page (NYSEAMERICAN:ATNM) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.